Entera Bio Stock Current Asset
| ENTX Stock | USD 1.59 0.03 1.85% |
Entera Bio fundamentals help investors to digest information that contributes to Entera Bio's financial success or failures. It also enables traders to predict the movement of Entera Stock. The fundamental analysis module provides a way to measure Entera Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Entera Bio stock.
Entera |
Entera Bio Company Current Asset Analysis
Entera Bio's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Entera Bio Current Asset | 8.46 M |
Most of Entera Bio's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Entera Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Entera Bio has a Current Asset of 8.46 M. This is 99.61% lower than that of the Biotechnology sector and 99.2% lower than that of the Health Care industry. The current asset for all United States stocks is 99.91% higher than that of the company.
Entera Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entera Bio's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entera Bio could also be used in its relative valuation, which is a method of valuing Entera Bio by comparing valuation metrics of similar companies.Entera Bio is currently under evaluation in current asset category among its peers.
Entera Fundamentals
| Return On Equity | -1.45 | ||||
| Return On Asset | -0.71 | ||||
| Operating Margin | (71.93) % | ||||
| Current Valuation | 50.48 M | ||||
| Shares Outstanding | 36.83 M | ||||
| Shares Owned By Insiders | 19.01 % | ||||
| Shares Owned By Institutions | 14.45 % | ||||
| Number Of Shares Shorted | 44.15 K | ||||
| Price To Earning | 2.10 X | ||||
| Price To Book | 8.85 X | ||||
| Price To Sales | 602.71 X | ||||
| Revenue | 14 K | ||||
| Gross Profit | 33 K | ||||
| EBITDA | (8.8 M) | ||||
| Net Income | (8.89 M) | ||||
| Cash And Equivalents | 17.28 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 390 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 10.89 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (7.31 M) | ||||
| Short Ratio | 1.98 X | ||||
| Earnings Per Share | (0.26) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.59 | ||||
| Market Capitalization | 59.67 M | ||||
| Total Asset | 11.77 M | ||||
| Retained Earnings | (104.39 M) | ||||
| Working Capital | 10.17 M | ||||
| Current Asset | 8.46 M | ||||
| Current Liabilities | 7.64 M | ||||
| Net Asset | 11.77 M |
About Entera Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Entera Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entera Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entera Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.